AlphAIalphai — Financial news for AI agents
SEC EDGARMAY 271 min read$ACAD

Kihara James sold $114K of ACAD

Kihara James (PRINCIPAL ACCOUNTING OFFICER) sold 5,401 shares of ACADIA PHARMACEUTICALS INC (ACAD) at $21.18 ($0.11M total) on 2026-05-26.

Original reporting
SEC EDGAR · Kihara James
Published May 27, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ACAD
Neutral
medium confidence
Mentioned
$ACAD
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACADNeutralLow
01

Why it matters

Insider sales can influence short-term sentiment, but without concurrent company catalysts (earnings, trial results, regulatory actions), the trading signal is typically low-confidence.

02

Market read

Traders may monitor for follow-on insider activity, but this single, small sale is unlikely to drive a sustained repricing absent other news.

03

What to watch

No 10b5-1 plan is indicated, but the article provides no context on compensation, tax obligations, or prior sale cadence; without trend data, inference is weak.

Relevance 6/10Timing: Immediate (new SEC Form 4 filing on 2026-05-27) but limited catalyst strength.

Background

The article is a SEC Form 4 insider transaction disclosure for Acadia Pharmaceuticals, showing an open-market sale by the principal accounting officer.

Company-level read

Ticker impact

$ACADNeutralMedium confidence
Context

Acadia Pharmaceuticals officer Kihara James sold 5,401 shares in an open-market transaction worth about $114.4K, disclosed via SEC Form 4.

Expected impact

Likely limited near-term impact; any move would be modest and sentiment-driven rather than thesis-changing.

Evidence & confidence

The filing is an ownership-change disclosure without accompanying company-specific news (no earnings, trial, deal, or guidance). The sale size is relatively small versus typical market float, and there is no stated 10b5-1 plan.

Market effects

Sector

Minimal; insider selling in a single biotech does not reliably reset sector expectations without additional operational/regulatory catalysts.

Regional

None indicated beyond routine US biotech sentiment.

Global

None indicated; filing is US insider disclosure only.

Counterpoint

What could challenge this read

The sale could be routine liquidity/portfolio management rather than a bearish signal, especially since the filing lacks any stated negative company event.

Key entities

  • issuer
    ACADIA PHARMACEUTICALS INC

    Subject of the insider transaction disclosure; officer sold 5,401 shares for ~$114.4K.

  • insider
    Kihara James

    Principal Accounting Officer who executed the open-market sale disclosed in the Form 4.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACAD insider trading history →

Related articles

AUG 28
$ACADHighAI 9/10

Did First-in-Class EU Approval for DAYBU Just Shift ACADIA Pharmaceuticals' (ACAD) Investment Narrative?

Acadia Pharmaceuticals (ACAD) received EU approval for DAYBU to treat Rett syndrome, based on Phase 3 trial data. This is the first authorized therapy for Rett syndrome in the EU, potentially opening a new market. The company is now in pricing and reimbursement negotiations. ACAD raised 2026 DAYBU sales guidance to $480M-$510M, with analysts projecting up to $1.9B in revenue. The approval strengthens ACAD's long-term diversification but near-term success depends on country-specific outcomes.

simplywall.st2 min
AUG 16
$ACADHighAI 9/10

Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript

Acadia Pharmaceuticals (NASDAQ:ACAD) reported Q2 2026 total revenues of $308 million, up 17% year over year, driven by DAYBUE and NUPLAZID demand. Management raised 2026 DAYBUE sales guidance to $480 million-$510 million and updated total revenue guidance to $1.24 billion-$1.30 billion. Cash and investments were $956 million as of June 30, 2026.

aol.com7 min
AUG 12
$ACADMed

Acadia Pharmaceuticals stock hits 52-week high at $29.81

Acadia Pharmaceuticals shares rose to a 52-week high around $29.76 to $29.81 and were about $29.77 at the time of reporting. The stock is up 36% over six months. Acadia reported Q2 2026 revenue of about $308 million versus a $296 million consensus, driven by Daybue sales of $125 million and steady Nuplazid. RBC, Oppenheimer, and Citizens raised price targets; analysts also cited upward earnings revisions and a Phase 2 RADIANT trial update.

investing.com4 min
AUG 12
$ACADMedAI 8/10

Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript

Acadia Pharmaceuticals (ACAD) reported Q2 2026 total revenues of $308 million, up 17% year over year, driven by DAYBUE and NUPLAZID demand. DAYBUE net sales were $125 million (+30%) and NUPLAZID net sales $183 million (+10%). 2026 sales guidance: DAYBUE $480-$510M, NUPLAZID $760-$790M, total revenue $1.24-$1.30B. Net income was $32M ($0.18/share).

fool.com7 min
AUG 6
$ACADMedAI 8/10

ACADIA Pharmaceuticals Q2 Earnings Call Highlights

Acadia Pharmaceuticals (NASDAQ:ACAD) raised its 2026 DAYBUE net sales guidance to $480 million to $510 million from $460 million to $490 million, citing expected initial European commercial sales in Q4. The company said the EMA CHMP issued a positive opinion for trofinetide and expects an EC decision later in Q3. Acadia kept 2026 NUPLAZID guidance at $760 million to $790 million and reported $956 million cash.

yahoo.com6 min